Failure of a human immunodeficiency virus (HIV) immune globulin to protect chimpanzees against experimental challenge with HIV - PubMed (original) (raw)

Failure of a human immunodeficiency virus (HIV) immune globulin to protect chimpanzees against experimental challenge with HIV

A M Prince et al. Proc Natl Acad Sci U S A. 1988 Sep.

Abstract

To assess the possible efficacy of passive immunization against human immunodeficiency virus (HIV) an immune globulin was prepared from plasma of HIV-seropositive donors selected to be among those having the top 12.5% of virus-neutralizing antibody titers. The immune globulin was treated with pepsin to render it intravenously tolerable. The preparation, which we termed HIVIG, neutralized 100 tissue culture 50% infective doses (TCID50) of HIV at an average dilution of 1:1000 in neutralization tests in vitro. During preparation HIVIG was subjected to virus inactivation and removal procedures that in theory resulted in a reduction in HIV infectivity by a factor of 10(25). At a dose of 9-10 ml/kg of body weight both the virus-inactivated source plasma and the final immunoglobulin preparation were noninfective and without adverse effect in two chimpanzees. Two chimpanzees inoculated intravenously with HIVIG at 1 ml/kg and two inoculated with 10 ml/kg were challenged intravenously 1 day later with 400 TCID50 of the same strain of HIV (HTLV-IIIb) used in neutralization assays in vitro. All animals became infected. Incubation periods to virus isolation (by cocultivation with human mononuclear cells) in HIVIG recipients did not differ significantly from the incubation period seen in a control animal that received a normal anti-HIV-free immunoglobulin. These findings may have implications for understanding the failure of experimental vaccines to protect against HIV challenge in chimpanzee experiments.

PubMed Disclaimer

Cited by

Statistical analysis of sparse infection data and its implications for retroviral treatment trials in primates.
Spouge JL. Spouge JL. Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7581-5. doi: 10.1073/pnas.89.16.7581. Proc Natl Acad Sci U S A. 1992. PMID: 1323844 Free PMC article.
Monocytotropic human immunodeficiency virus type 1 (HIV-1) variants detectable in all stages of HIV-1 infection lack T-cell line tropism and syncytium-inducing ability in primary T-cell culture.
Schuitemaker H, Kootstra NA, de Goede RE, de Wolf F, Miedema F, Tersmette M. Schuitemaker H, et al. J Virol. 1991 Jan;65(1):356-63. doi: 10.1128/JVI.65.1.356-363.1991. J Virol. 1991. PMID: 1985204 Free PMC article.
Effects of inefficient cleavage of the signal sequence of HIV-1 gp 120 on its association with calnexin, folding, and intracellular transport.
Li Y, Bergeron JJ, Luo L, Ou WJ, Thomas DY, Kang CY. Li Y, et al. Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9606-11. doi: 10.1073/pnas.93.18.9606. Proc Natl Acad Sci U S A. 1996. PMID: 8790377 Free PMC article.
Importance of ribosomal frameshifting for human immunodeficiency virus type 1 particle assembly and replication.
Hung M, Patel P, Davis S, Green SR. Hung M, et al. J Virol. 1998 Jun;72(6):4819-24. doi: 10.1128/JVI.72.6.4819-4824.1998. J Virol. 1998. PMID: 9573247 Free PMC article.
Antibody-dependent enhancement of simian immunodeficiency virus (SIV) infection in vitro by plasma from SIV-infected rhesus macaques.
Montefiori DC, Robinson WE Jr, Hirsch VM, Modliszewski A, Mitchell WM, Johnson PR. Montefiori DC, et al. J Virol. 1990 Jan;64(1):113-9. doi: 10.1128/JVI.64.1.113-119.1990. J Virol. 1990. PMID: 2152808 Free PMC article.

References

1. Proc Natl Acad Sci U S A. 1985 Jul;82(14):4813-7 - PubMed
1. Nature. 1977 Feb 24;265(5596):739-41 - PubMed
1. Lancet. 1986 Mar 29;1(8483):706-10 - PubMed
1. J Virol. 1986 Dec;60(3):1141-4 - PubMed
1. Clin Immunol Immunopathol. 1984 Feb;30(2):330-5 - PubMed

Failure of a human immunodeficiency virus (HIV) immune globulin to protect chimpanzees against experimental challenge with HIV - PubMed (original) (raw)